Latest placebo Stories
ENGLEWOOD, Colo., May 21, 2015 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced positive results of the OptimEyes trial for DME.
- EXPEDITION trial results demonstrated QVA149 (indacaterol/glycopyrronium) met all primary and secondary endpoints(1),(2),(3),(4) EAST HANOVER, N.J., May 20, 2015 /PRNewswire/ -- Today, Novartis
Phase 3 Clinical Trial in Uncontrolled Persistent Asthma Underway TARRYTOWN, N.Y. and PARIS, May 18, 2015 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.
Long-term OFEV treatment in the INPULSIS® extension study reinforces the safety and tolerability profile for up to 33 months in patients with IPF RIDGEFIELD, Conn., May 18, 2015 /PRNewswire/
TOKYO and SAN FRANCISCO, May 17, 2015 /PRNewswire/ -- Astellas Pharma Inc (TSE:4503) and Medivation, Inc (NASDAQ: MDVN) today announced data from the Phase 2 STRIVE trial comparing enzalutamide and
Patients Reported Significant Reductions in Monthly Migraine Days in First Dose-Ranging Study of CGRP Receptor Antagonist THOUSAND OAKS, Calif., May 15, 2015 /PRNewswire/ -- Amgen
DUBLIN and RALEIGH, N.C., May 14, 2015 /PRNewswire/ -- Endo Pharmaceuticals Inc., a subsidiary of Endo International plc (NASDAQ: ENDP) (TSX: ENL), and BioDelivery Sciences International, Inc.
ADYX003, Randomized, Placebo-Controlled Study to Evaluate Safety and Efficacy of Two Dose-Volume Levels of AYX1 for the Prevention of Pain Following Total Knee Replacement SAN FRANCISCO,
ROSEMONT, Ill., May 6, 2015 /PRNewswire-USNewswire/ -- Shock wave therapy may relieve symptoms in up to 65 percent of patients suffering from chronic
-- Conference Call and Webcast Today at 5:00 p.m. ET -- FREMONT, Calif., May 5, 2015 /PRNewswire/ -- Ardelyx, Inc.
- A woman chauffeur.
- A woman who operates an automobile.